Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Consensus "Moderate Buy": 11 brokerages cover Roivant with a consensus Moderate Buy (9 buys, 1 hold, 1 sell) and an average 12‑month price target of $29.50.
• Heavy insider selling: Insiders sold 4,595,624 shares worth about $124.85 million in the past 90 days, leaving insiders with 10.8% ownership.
• Institutional ownership and stock metrics: Hedge funds and institutions own 64.76% of the stock; Invesco boosted its stake to 2.28M shares, and Roivant trades near $29 with a market cap of $20.84 billion and a negative P/E (-24.89).

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $29.50.

ROIV has been the topic of a number of analyst reports. Weiss Ratings downgraded shares of Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, February 9th. HC Wainwright lifted their target price on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a "buy" rating in a research note on Wednesday, March 4th. Citigroup lifted their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a "buy" rating in a research note on Tuesday, February 10th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, Sanford C. Bernstein began coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They issued an "outperform" rating and a $35.00 price target on the stock.

Insiders Place Their Bets

In other news, CAO Jennifer Humes sold 13,538 shares of the business's stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the sale, the chief accounting officer directly owned 84,191 shares of the company's stock, valued at approximately $2,388,498.67. The trade was a 13.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Melissa B. Epperly sold 41,861 shares of the business's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the completion of the sale, the director directly owned 15,804 shares in the company, valued at $453,258.72. This trade represents a 72.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 4,595,624 shares of company stock worth $124,848,136. Insiders own 10.80% of the company's stock.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Creek Drive Management Group LLC purchased a new stake in shares of Roivant Sciences in the 4th quarter valued at approximately $3,689,000. Hsbc Holdings PLC purchased a new stake in shares of Roivant Sciences in the 4th quarter valued at approximately $896,000. Pacer Advisors Inc. raised its stake in shares of Roivant Sciences by 24.0% in the 4th quarter. Pacer Advisors Inc. now owns 70,259 shares of the company's stock valued at $1,525,000 after acquiring an additional 13,609 shares during the period. Dorsey Wright & Associates purchased a new stake in shares of Roivant Sciences in the 4th quarter valued at approximately $8,162,000. Finally, Invesco Ltd. raised its stake in shares of Roivant Sciences by 28.9% in the 4th quarter. Invesco Ltd. now owns 2,281,487 shares of the company's stock valued at $49,508,000 after acquiring an additional 512,129 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $29.12 on Wednesday. The firm's 50-day moving average is $27.68 and its two-hundred day moving average is $22.94. Roivant Sciences has a 12 month low of $9.90 and a 12 month high of $30.33. The company has a market capitalization of $20.84 billion, a PE ratio of -24.89 and a beta of 1.20.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.